LifeMD FY2025 rev $194.1M (+25%), adj EBITDA $15.3M (+309%); guides to >$250M run-rate by Q4 2026

LifeMD, Inc.

FY2025 revenue $194.1M (+25% YoY); adjusted EBITDA $15.3M (+309% YoY).
Q4 2025 revenue $46.9M (+4% YoY); adjusted EBITDA $4.8M (+348% YoY).
Launched oral Wegovy post-year-end; >80% of new weight management patients using branded therapy; Q1 sign-ups at record levels.
Ended 2025 with $36.8M cash, no debt; guides to annualized revenue >$250M and adj EBITDA >$25M by Q4 2026.
Benefits infrastructure on track to cover ~220M Americans in Q2 2026; women's health seeing strong early growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.